ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Toxicity concerns send Larimar down
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
FDA sends Reata back to the drawing board
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Marinus finds a path forward in rare epilepsies
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
